Hostname: page-component-745bb68f8f-cphqk Total loading time: 0 Render date: 2025-01-11T03:59:34.839Z Has data issue: false hasContentIssue false
  • English
  • Français

Novel Treatments for Major Depressive Disorder

Published online by Cambridge University Press:  07 November 2014

R. Bruce Lydiard
Get access Rights & Permissions [Opens in a new window]

Extract

Data from a variety of studies, including the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, have shown that fewer patients achieve remission from symptoms of major depressive disorder (MDD) and other depressive disorders after taking the first-prescribed antidepressant treatment than was expected. The goal of treatment is true remission: the complete absence of symptoms. Achieveing less than true remission is associated with MDD recurrence and continued impairment.

Type
Expert Panel Supplement
Information
CNS Spectrums , Volume 14 , Issue S5: Efficacy, Safety, and Tolerability Considerations in the Novel Treatment of Major Depressive Disorder , March 2009 , pp. 11 - 13
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.CrossRefGoogle ScholarPubMed
2.Thase, ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004;9(11):808–816; 818–821.CrossRefGoogle ScholarPubMed
3.Bodkin, JA, Lasser, RA, Wines, JD Jr, Gardner, DM, Baldessarini, RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58(4):137–145.CrossRefGoogle ScholarPubMed
4.Marshall, RD, Liebowitz, MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol. 1996;16(1):80–81.CrossRefGoogle ScholarPubMed
5.Spier, SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7(2):73–75.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
6.Patkar, AA, Masand, PS, Pae, CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653–656.CrossRefGoogle ScholarPubMed
7.DeBattista, C, Doghramji, K, Menza, MA, Rosenthal, MH, Fieve, RR, and the Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(9):1057–1064.CrossRefGoogle ScholarPubMed
8.Shelton, RC, Papakostas, GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008;117(4):253–259.CrossRefGoogle ScholarPubMed
9.Rapaport, MH, Gharabawi, GM, Canuso, CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31(11):2505–2513.CrossRefGoogle ScholarPubMed
10.Berman, RM, Marcus, RN, Swanink, R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–853.CrossRefGoogle ScholarPubMed
11.Marcus, RN, McQuade, RD, Carson, WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–165.CrossRefGoogle ScholarPubMed
12.Papakostas, GI, Shelton, RC, Smith, J, Fava, M. Augmentation of antidepressants with atypical antipsy-chotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826–831.CrossRefGoogle Scholar
13.Smith, WT, Londborg, PD, Glaudin, V, Painter, JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry. 1998;155(10):1339–1345.CrossRefGoogle ScholarPubMed
14.Krystal, A, Fava, M, Rubens, R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluox-etine for insomnia with coexisting depression. J Clin Sleep Med. 2007;3(1):48–55.Google Scholar
15.Lydiard, RB, Otto, MW, Milrod, B. Panic Disorder. In: Gabbard, GO, ed. Treatments of Psychiatric Disorders. 3rd ed.Arlington, VA: American Psychiatric Association; 2001:247–282.Google Scholar
16.Normann, C, Hummel, B, Schärer, LO, Hörn, M, Grunze, H, Walden, J. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry. 2002;63(4):337–344.CrossRefGoogle ScholarPubMed
17.Fava, M. Augmenting antidepressants with folate: a clinical perspective. J Clin Psychiatry. 2007;68(suppl 10):4–7.Google ScholarPubMed
18.Thase, ME, Friedman, ES, Biggs, MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164(5):739–752.CrossRefGoogle Scholar
19.Marangell, LB, Martinez, M, Jurdi, RA, Zboyan, H: Neurostimulation therapies in depression: a review of new modalities. Acta Psychiatr Scand. 2007;116(3):174–181.CrossRefGoogle ScholarPubMed
20.Kennedy, SH, Giacobbe, P. Treatment resistant depression--advances in somatic therapies. Ann Clin Psychiatry. 2007;19(4):279–287.CrossRefGoogle ScholarPubMed